AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

FDA Updates Stribild Labeling
On August 28, 2014, FDA approved updates to the label for Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir 300 mg) fixed-dose combination tablets. The label was updated with efficacy, resistance, and safety data from two clinical trials; renal information; and drug interaction information. The updated labeling for Stribild is available at the FDA website.  More information is available:  FDA: Press release AIDSinfo: Patient fact sheet on Stribild (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - September 12, 2014 Category: Infectious Diseases Source Type: news

News from CDC and NIAID
From CDC: August 27, 2014: New CDC Campaign Urges Latinos to Speak Up About HIV From NIAID: August 26, 2014: HIV Antibodies Block Infection by Reservoir-Derived Virus in Laboratory Study (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news

FDA Updates Etravirine Labeling
"On August 20, 2014, the Intelence (etravirine) label was updated to include information regarding coadministration of etravirine with the following drugs: "dolutegravir, dolutegravir/darunavir/ritonavir, dolutegravir/lopinavir/ritonavir "atazanavir/ritonavir "boceprevir" The updated labeling for etravirine is available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on etravirine (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health an...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news

FDA Approves New Fixed-Dose Combination Drug, Triumeq (Abacavir Sulfate/Dolutegravir/Lamivudine), to Treat HIV Infection
"On August 22, 2014, FDA approved a new fixed-dose combination product: TRIUMEQ, a combination of dolutegravir (integrase strand transfer inhibitor), abacavir sulfate and lamivudine (both nucleoside analogue reverse transcriptase inhibitors) for the treatment of HIV-1 infection.  "TRIUMEQ alone is not recommended for use in patients with current or past history of resistance to any components of TRIUMEQ. "TRIUMEQ alone is not recommended in patients with resistance-associated integrase substitutions or clinically suspected integrase strand transfer inhibitor resistance because the dose of dolut...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 29, 2014 Category: Infectious Diseases Source Type: news

NIH-Led Scientists Boost Potential of Passive Immunization Against HIV
"Scientists are pursuing injections or intravenous infusions of broadly neutralizing HIV antibodies (bNAbs) as a strategy for preventing HIV infection. This technique, called passive immunization, has been shown to protect monkeys from a monkey form of HIV called simian human immunodeficiency virus, or SHIV. To make passive immunization a widely feasible HIV prevention option for people, scientists want to modify bNAbs such that a modest amount of them is needed only once every few months. "To that end, an NIH-led team of scientists has mutated the powerful anti-HIV bNAb called VRC01 so that, once infused into m...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 15, 2014 Category: Infectious Diseases Source Type: news

AIDSinfo Glossary App Updated for iOS 7
The free AIDSinfo HIV/AIDS Glossary apps for Apple and Android devices provide on-the-go access to definitions for more than 700 HIV/AIDS-related terms in English and Spanish. The apps also include an audio feature so users can hear the correct pronunciation of each term.   The Glossary app for iPhone, iPad, and iPod touch is now optimized for iOS7. The updated app features an iOS7-compatible look and feel and a new icon. The upgrade also included minor bug fixes.   Whether you are new to the Glossary app or a long-time user, download the latest, iOS7-optimized version of the app for your Apple device today. Feed...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 15, 2014 Category: Infectious Diseases Source Type: news

News from NIAID
July 24, 2014: Powerful HIV Antibodies May Require Assist from Second Antibody to Develop July 21, 2014: At AIDS 2014, Dr. Anthony S. Fauci Discusses Key Challenges in HIV Scientific Discovery: Cure, Vaccine  July 21, 2014: NIH-Supported Scientists Demonstrate Very Early Formation of SIV Reservoir July 19, 2014: HIV Cure Research: Where We Are, Where We Are Headed (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 1, 2014 Category: Infectious Diseases Source Type: news

AIDSinfo HIV/AIDS Awareness Day Widget Now Available
AIDSinfo is pleased to announce the release of our HIV/AIDS Awareness Day widget! Add the widget to your website or blog to display the logos for the national HIV/AIDS awareness days. The logos will link to the AIDSinfo HIV/AIDS awareness day pages. The widget also provides links to the infoSIDA HIV/AIDS awareness day pages.  Along with our HIV/AIDS awareness day widget, we also have a widget for our news feed. Add this widget to your website to display the latest HIV/AIDS treatment, prevention, and research news. Instructions for adding the widgets to your website can be found on the AIDSinfo widget page.  Qu...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - August 1, 2014 Category: Infectious Diseases Source Type: news

Study Suggests That Low Levels of HIV-1 RNA Detected in the Cerebrospinal Fluid After Up to 10 Years of Suppressive Therapy Are Associated With Local Immune Activation
We examined the frequency and magnitude of persistent low-level HIV-1 RNA in CSF and its relation to the central nervous system (CNS) immune activation. … "CSF and plasma HIV-1 RNA were measured using the single-copy assay with a detection limit of 0.3 copies/ml in 70 CSF and 68 plasma samples from 45 treated HIV-1-infected patients with less than 40 copies/ml of HIV-1 RNA in both fluids by standard clinical assays. … "CSF HIV-1 RNA was detected in 12 of the 70 CSF samples (17%) taken after up to 10 years of suppressive therapy, compared to 39 of the 68 plasma samples (57%) with a median concentra...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 18, 2014 Category: Infectious Diseases Source Type: news

"Mississippi Baby" Now Has Detectable HIV, Researchers Find
"The child known as the 'Mississippi baby'—an infant seemingly cured of HIV that was reported as a case study of a prolonged remission of HIV infection in The New England Journal of Medicine last fall—now has detectable levels of HIV after more than two years of not taking antiretroviral therapy without evidence of virus, according to the pediatric HIV specialist and researchers involved in the case. "'Certainly, this is a disappointing turn of events for this young child, the medical staff involved in the child’s care, and the HIV/AIDS research community,' said NIAID Director Anthony S. F...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 18, 2014 Category: Infectious Diseases Source Type: news

AIDSinfo Offers an Easy Way to Find HIV/AIDS-Related Clinical Trials
The AIDSinfo and infoSIDA clinical trial search tools make it easy to find HIV/AIDS-related clinical trials. Whether you are searching for trials accepting volunteers, looking for trials in a specific area of interest, or checking for clinical trial results, the search tool makes the job easy. Use the "Search by Category" menu to browse more than 180 preconfigured searches on a variety of topics. Categories include opportunistic infections, side effects, HIV-related drugs, prevention research, and much more. Once you select your search, you can click the "Refine Search" button on the results page ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 3, 2014 Category: Infectious Diseases Source Type: news

Updated Recommendations for Laboratory Testing for the Diagnosis of HIV Infection
CDC and the Association of Public Health Laboratories (APHL) recently issued Updated Recommendations for Laboratory Testing for the Diagnosis of HIV Infection. This document also offers approaches for reporting test results to people ordering HIV tests and to public health authorities. The recommended algorithm is a sequence of tests used in combination to improve the accuracy of the laboratory diagnosis of HIV based on testing of serum or plasma specimens. More information is available: CDC: Quick Reference Guide - Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations  CDC: Suggeste...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - July 3, 2014 Category: Infectious Diseases Source Type: news

New Pediatric Dosage Form and Label Changes for Reyataz (Atazanavir)
"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label." The updated labeling for atazanavir is available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on atazanavir (Source: AIDSinfo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 20, 2014 Category: Infectious Diseases Source Type: news

Changes to the Complera (Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate) Labeling
"On June 5, 2014, FDA approved changes to the Complera (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) fixed-dose combination tablet labeling to include rilpivirine dose adjustment information when Complera is coadministered with rifabutin." The updated labeling for Complera is available at the FDA website. More information is available: FDA: Press release AIDSinfo: Patient fact sheet on Complera (Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS))
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 20, 2014 Category: Infectious Diseases Source Type: news

June 27 is National HIV Testing Day
According to the Centers for Disease Control and Prevention (CDC), about 50,000 people get infected with HIV each year in the United States. However, 1 in 6 people living with HIV don’t know that they are infected. National HIV Testing Day is observed each year on June 27 to highlight the importance of HIV testing. CDC recommends that everyone between the ages of 13 and 64 get tested for HIV at least once as part of their routine health care. Regardless of age, people at high risk of HIV should get tested more often. Visit the AIDSinfo National HIV Testing Day webpage [en español] to learn more about HIV tes...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 20, 2014 Category: Infectious Diseases Source Type: news